Clinical Evaluation of the Oncology Malignancies by Using Biosensors
Abstract
The rapid, economical, and sensitive diagnostic methods for the detection of cancer are of tremendous importance for clinical applications. These methods could enable rapid, point-of-care (POC) applications requiring immediate diagnosis. The traditional diagnostic and detection methodologies have their own limitations, like the need of complex and expensive instrument. Biosensors have received much attention in recent years. The biosensors can centrally serve as low-cost and highly able devices that are capable of detecting specific biological analytes and help to analyze various cancer by the help of different biomarkers, which are present in the body. This review focuses on the role of biosensors for oncology disorders particularly in the field of oncohematology. Biosensors have recently been developed in order to improve the diagnosis and treatment of patients affected by oncology malignancies. The review also considers the challenges and future perspectives of biosensors in clinical practice of oncology disorder. Keywords: Acute myeloid leukemia, chronic myeloid leukemia, leukemia, oncohematologyReferences
Ronkainen N.J. Nanomaterial-based electrochemical immunosensors for clinically significant biomarkers, Open Acess J. 2014; 7: 4669–9p. 2. Hasan A., Memic A., Annabi N. “Electrospin scaffolds for tissue engineering of vascular grafts,”Acta Biomater. 2014; 10: 11–25p.
Ottou F.G. Peripheralblood 8 colour flow cytometry monitoring of hairy cell leukaemia allows detection of high‐risk patients, Wiley Online J. 2014; 8: 54–75p.
Wilson M.S., Nie W, Multiplex measurement of seven tumor markers using an electrochemical protein chip, Anal. Chem. 2006; 78: 6476–83p.
Wu J., Yan F., Tang J., et al. A disposable multianalyte electrochemical immunosensor array for automated simultaneous determination of tumor markers, Clin Chem. 2007; 1495–1502p.
Pimková K., Bocková M., Hegnerová K., et al. Surface plasmon resonance biosensor for the detection of VEGFR-1 – A protein marker of
myelodysplastic syndromes, Anal Bioanal Chem. 2012; 402: 381–7p.
Rasooly A., Jacobson J. Development of biosensors for cancer clinical testing, Biosens Bioelectron. 2006; 21; 1851–8p.
Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis, J Biochem Mol Biol. 2006; 39; 469–78p.
Medley C.D., Smith J.E., Tang Z., et al. Nanoparticle-based colorimetric assay for the direct detection of cancerous cells, Anal Chem. 2008; 80: 1067–72p.
Herzenberg L.A., Parks D., Sahaf B., et al. The historyand future of the fluorescence activated cell sorter and flow cytometry: a view from Stanford, Clin Chem. 48: 1819–27p.
Chabanas A., Rambeaud J.J., Huo H.H., et al. Limits of flow-cytometry histogram analysis methods to assess bladder tumour antigen expression, Anal Cell Pathol. 1997; 13; 39–47p.
Piatkowska-Jakubas B., Krawczyk-Kuliś M., Giebel S., et al. Use of L-asparaginase in acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group, Pol Arch Med Wewn. 2008; 118: 664–9p.
Hiddemann W., Buchner T. Current status and perspectives of therapies for acute myeloid leukaemia, Semin Hematol. 2001; 38: 3–9p.
Alloush H.M., Anderson E., Martin A.D., et al. A bioluminescent microbial biosensor for in vitro pretreatment assessment of cytarabine efficacy in leukemia, Clin Chem. 2010; 56: 1862–70p.
Mizutani T., Kondo T., Darmanin S., et al. Novel FRET-based biosensor for the measurement of BCR-ABL activity and its response to drugs in living cells, Clin Cancer Res. 2010; 16: 3964–75p.
